Using prostate cancer risk calculators may help to identify risk and aid in clinical decision-making, according to a regional study published in the Irish Journal of Medical Science.
Researchers led by Robert Foley, MD, of the University College Dublin examined data from 337 men at a referral center in Ireland using calibration analysis, receiver operating characteristic (ROC) analysis, and decision curve analysis.
They wanted to validate the performance of the prostate cancer prevention trial (PCPT) as well as the European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculators.
After consecutive biopsies, prostate cancer was diagnosed in 146 men, with 98 at high grade. The area under the curve for the PCPT and ERSPC risk calculators were found to be 0.68 and 0.66, respectively.
RELATED: Cardiovascular Risk in Men with Prostate Cancer on GnRH Agonist Therapy
The authors found that, upon decision curve analysis, the risk calculators demonstrated a net benefit in diagnosing prostate cancer risk.
“The PCPT and ERSPC risk calculators achieve a statistically significant prediction of prostate cancer in this Irish population,” they concluded.